文献速递贫血与红细胞疾病

多层次移动健康干预提升镰状细胞病患者羟基脲依从性

A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease.
PubMed 文献 · Blood Adv · 2023-01-01

这项多中心非随机试验纳入293例15-45岁镰状细胞病患者,评估针对患者(InCharge Health)和针对医生(HU Toolbox)的移动健康干预对羟基脲依从性的影响。干预24周及研究后12周与干预前24周比较,235例可评估者平均覆盖天数百分比从39.7%升至56.0%(P<0.001)并维持,平均HbF从10.95%升至12.78%(P=0.03),自报疼痛频率下降,但仅11.2%的医生平均每月使用HU Toolbox至少1次且未影响依从性变化。

要点

  • 患者端移动健康应用InCharge Health使平均覆盖天数百分比从39.7%升至56.0%并维持。
  • 平均HbF从10.95%升至12.78%,自报疼痛频率从3.54降至3.35次/年。
  • 医生端工具HU Toolbox仅11.2%的医生平均每月使用至少1次,未影响依从性变化。

核心结论

  • 针对羟基脲依从性障碍定制移动健康方案可能改善依从性并带来临床获益,但需一项确证性随机研究。

研究设计与样本

  • 多中心非随机试验,纳入293例15-45岁镰状细胞病患者,比较干预24周及研究后12周与干预前24周 interval。
  • 可评估患者235例,其中51%为男性,中位年龄27.5岁,86.8%为HbSS/HbSβ0-地中海贫血。

主要发现

  • 235例可评估者平均覆盖天数百分比从39.7%升至56.0%(P<0.001),并维持于51.4%(P<0.001)。
  • 平均HbF从10.95%升至12.78%(P=0.03),自报疼痛频率从3.54降至3.35次/年(P=0.041)。
  • 199/235例(84.7%)使用InCharge Health至少1天,中位使用天数占研究天数17%(IQR 4.8-45.8%)。
  • 基线有至少1次疼痛住院者,每24周住院次数从基线至24周由1.97降至1.48次/患者(P=0.0045),25-36周为1.25次/患者(P=0.0015)。
  • 覆盖天数百分比随应用使用增加(P<0.001),在私人保险者(P=0.0078)、年长者(P=0.033)和疼痛干扰较低者(P=0.0012)中效应最大。

临床怎么用

  • 作者认为,针对羟基脲依从性障碍定制移动健康方案可能改善依从性并带来临床获益。
  • 作者指出需一项确证性随机研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hydroxyurea reduces sickle cell disease (SCD) complications, but medication adherence is low. We tested 2 mobile health (mHealth) interventions targeting determinants of low adherence among patients (InCharge Health) and low prescribing among providers (HU Toolbox) in a multi-center, non-randomized trial of individuals with SCD ages 15-45. We compared the percentage of days covered (PDC), labs, healthcare utilization, and self-reported pain over 24 weeks of intervention and 12 weeks post-study with a 24-week preintervention interval. We enrolled 293 patients (51% male; median age 27.5 years, 86.8% HbSS/HbSβ0-thalassemia). The mean change in PDC among 235 evaluable subjects increased (39.7% to 56.0%; P < 0.001) and sustained (39.7% to 51.4%, P < 0.001). Mean HbF increased (10.95% to 12.78%; P = 0.03). Self-reported pain frequency reduced (3.54 to 3.35 events/year; P = 0.041). InCharge Health was used ≥1 day by 199 of 235 participants (84.7% implementation; median usage: 17% study days; IQR: 4.8-45.8%). For individuals with ≥1 baseline admission for pain, admissions per 24 weeks declined from baseline through 24 weeks (1.97 to 1.48 events/patient, P = 0.0045) and weeks 25-36 (1.25 events/patient, P = 0.0015). PDC increased with app use (P < 0.001), with the greatest effect in those with private insurance (P = 0.0078), older subjects (P = 0.033), and those with lower pain interference (P = 0.0012). Of the 89 providers (49 hematologists, 36 advanced care providers, 4 unreported), only 11.2% used HU Toolbox ≥1/month on average. This use did not affect change in PDC. Tailoring mHealth solutions to address barriers to hydroxyurea adherence can potentially improve adherence and provide clinical benefits. A definitive randomized study is warranted. This trial was registered at www.clinicaltrials.gov as #NCT04080167.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hankins JS, Brambilla D, Potter MB, et al. A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease. Blood Adv. 2023. PMID: 37738155. doi:10.1182/bloodadvances.2023010670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。